Management of ankylosing spondylitis with infliximab
Éric Toussirot1,2,3, Ewa Bertolini1, Daniel Wendling1,21Rheumatology, University Hospital Jean Minjoz, Besançon, France; 2Equipe d’Accueil 3186 “Agents pathogènes et Inflammation” University of Franche-Comt&am...
Guardado en:
Autores principales: | Éric Toussirot, Ewa Bertolini, Daniel Wendling |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f7446406be53441a95382372855bd969 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach A, et al.
Publicado: (2014) -
The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases
por: Jeffrey R. Curtis, et al.
Publicado: (2021) -
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: Fabrizio Cantini, et al.
Publicado: (2009) -
Serum IL-6 correlates with axial mobility index (Bath Ankylosing Spondylitis Metrology Index) in Brazilian patients with ankylosing spondylitis
por: Rabelo CF, et al.
Publicado: (2018) -
Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
por: Tahir H, et al.
Publicado: (2020)